Toll‐like receptor ligands as adjuvants in allergen‐specific immunotherapy
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Background Allergen‐specific immunotherapy (SIT) leads to long‐term amelioration of T‐helper type 2 (Th2)‐mediated allergic symptoms and is therefore recommended as a first line therapy for allergies. The major disadvantage of SIT is its low efficiency, requiring treatment over years. Objective In this study, we evaluated the potential of Toll‐like receptor (TLR) ligands to facilitate Th1‐type immune responses. Methods The immunogenicity and therapeutic potential of the major bee venom allergen phospholipase A2 (PLA2) combined with various TLR ligands were tested in mice and compared with immune responses induced by conventional aluminium‐based preparations. Results Regarding total IgG against PLA2, TLR2/4‐binding lipopolysaccharide and TLR3‐binding polyriboinosinic polyribocytidylic (PolyI:C) were the superior adjuvants for prophylactic vaccination. However, TLR9‐binding phosphorothioate‐modified cytosine–guanosine‐rich oligonucleotide (CpG), TLR‐3‐binding PolyI:C, and TLR2/6‐binding peptidoglycan skewed the immune responses more towards IgG2a isotype and Th1 cytokines. Furthermore, in a therapeutic approach, CpG, PolyI:C and TLR7/8‐binding 3M003 had immune modulating properties as they suppressed established IgE titres. Conclusion The potential of TLR ligands to adjuvate the immunogenicity of bee venom PLA2 and to skew the Th1–Th2 balance proved very heterogeneous. With respect to SIT, CpG, PolyI:C, and 3M003 were very promising. Hence, TLR ligands should be considered as adjuvants or immune modulators in SIT in human as to improve its efficiency regarding the Th1–Th2 balance of the immune response with a likely effect on therapy duration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964
TLRs: Professor Mechnikov, sit on your hat
O'Neill, L. A. J. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.10.005 · Cited by 140
Cited by
Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections
Senti, G., Crameri, R., Kuster, D., Johansen, P., Martinez-Gomez, J. M., Graf, N., Steiner, M., Hothorn, L. A., Grönlund, H., Tivig, C., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.026 · Cited by 271
Self-citationA Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles
Gómez, J. M. M., Fischer, S., Csaba, N., Kündig, T. M., Merkle, H. P., Gander, B., & Johansen, P. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9318-0 · Cited by 63
Self-citationmRNA vaccination as a safe approach for specific protection from type I allergy
Weiss, R., Scheiblhofer, S., Roesler, E., Weinberger, E., & Thalhamer, J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.168 · Cited by 42
Novel Delivery Routes for Allergy Immunotherapy
Senti, G., & Kündig, T. M. (2016) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.08.006 · Cited by 41
Self-citationNovel strategies for the treatment of grass pollen-induced allergic rhinitis
Larsson, O., Hellkvist, L., Peterson-Westin, U., & Cardell, L. O. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1190829 · Cited by 16
Metadata
- Authors
- Johansen, P., Senti, G., Martinez Gomez, J. M., Storni, T., von Beust, B. R., Wüthrich, B., Bot, A., & Kündig, T. M.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2005-12
- Volume
- 35
- Issue
- 12
- Pages
- 1591-1598
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2031631061
- Cited by
- 57
- References
- 2
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toll‐like receptor ligands as adjuvants in allergen‐specific immunotherapy. https://app.cochat.ai/papers/10.1111/j.1365-2222.2005.02384.x
- The paper
- Johansen, P., Senti, G., Martinez Gomez, J. M., Storni, T., von Beust, B. R., Wüthrich, B., Bot, A., & Kündig, T. M. (2005). Toll‐like receptor ligands as adjuvants in allergen‐specific immunotherapy. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2005.02384.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.